BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 25038505)

  • 1. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.
    Danielsen SA; Lind GE; Kolberg M; Høland M; Bjerkehagen B; Sundby Hall K; van den Berg E; Mertens F; Smeland S; Picci P; Lothe RA
    Neuro Oncol; 2015 Jan; 17(1):63-9. PubMed ID: 25038505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.
    Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY
    Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
    Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
    Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.
    Cleven AH; Sannaa GA; Briaire-de Bruijn I; Ingram DR; van de Rijn M; Rubin BP; de Vries MW; Watson KL; Torres KE; Wang WL; van Duinen SG; Hogendoorn PC; Lazar AJ; Bovée JV
    Mod Pathol; 2016 Jun; 29(6):582-90. PubMed ID: 26990975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.
    LaFemina J; Qin LX; Moraco NH; Antonescu CR; Fields RC; Crago AM; Brennan MF; Singer S
    Ann Surg Oncol; 2013 Jan; 20(1):66-72. PubMed ID: 22878618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.
    Dubbink HJ; Bakels H; Post E; Zwarthoff EC; Verdijk RM
    J Neurooncol; 2014 Nov; 120(2):267-72. PubMed ID: 25035100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
    Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
    Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Nguyen R; Jett K; Harris GJ; Cai W; Friedman JM; Mautner VF
    J Neurooncol; 2014 Jan; 116(2):307-13. PubMed ID: 24166582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis.
    Koga T; Iwasaki H; Ishiguro M; Matsuzaki A; Kikuchi M
    J Pathol; 2002 May; 197(1):98-107. PubMed ID: 12081210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours.
    Harder A; Rosche M; Reuss DE; Holtkamp N; Uhlmann K; Friedrich R; Mautner VF; von Deimling A
    Eur J Cancer; 2004 Dec; 40(18):2820-8. PubMed ID: 15571966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis.
    Lim Z; Gu TY; Tai BC; Puhaindran ME
    World J Surg Oncol; 2024 Jan; 22(1):14. PubMed ID: 38191386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location.
    Kamran SC; Howard SA; Shinagare AB; Krajewski KM; Jagannathan JP; Hornick JL; Ramaiya NH
    Eur J Surg Oncol; 2013 Jan; 39(1):46-52. PubMed ID: 23084090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.
    Park SJ; Sawitzki B; Kluwe L; Mautner VF; Holtkamp N; Kurtz A
    BMC Med; 2013 Apr; 11():109. PubMed ID: 23618374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.